|Bid||11.99 x 0|
|Ask||12.05 x 0|
|Day's Range||11.55 - 11.68|
|52 Week Range||9.46 - 27.63|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
These three health and technology stocks are seeing technical strength ahead of upcoming earnings. Evolus, Inc. (NASDAQ: EOLS ) gained 50 cents to $26.44 on 537,100 shares Wednesday. The performance beauty ...
In his second "Executive Decision" segment of Mad Money Thursday night, Jim Cramer sat down with David Moatazedi, president and CEO of Evolus Inc. with a new drug to compete with Botox. Shares of EOLS have surged from $16 to $29 after the company received FDA approval on Friday.
Billionaire David Tepper, president of hedge fund Appaloosa LP, fired off a letter Tuesday demanding the Dublin-based pharmaceutical firm separate the roles of chairman and CEO. Following the release of the letter, Allergan's stock fell 0.4% Tuesday to close at $138.01. "The Board of Directors is committed to strong governance practices and independent board leadership," Allergan said in its statement.
Stocks that moved substantially or traded heavily on Monday: Papa John's International Inc., up $ 3.46 to $41.97 The head of the investment firm Starboard Value is being named board chairman at the troubled ...
shares fell almost 4% and Evolus Inc. shares gained almost 12% Monday after the U.S. Food and Drug Administration approved Evolus's new wrinkle treatment for adult patients which is expected to rival Allergan's Botox. The treatment, called Jeuveau, received FDA approval late Friday, some eight months after the agency first rejected the application citing deficiencies in its manufacturing and chemical composition.
Drug makers were active Monday, led by Alexion and Bristol-Myers Squibb, as stocks opened mixed and the Dow Jones industrials dug in to hold 25,000.
An injection to treat forehead wrinkles is set to rival Allergan's Botox after U.S. regulators approved Evolus Inc's cheaper treatment on Friday, sending its shares up about 5 percent after the bell. The approval of Evolus's Jeuveau to treat frown lines comes about eight months after the agency declined to approve the drug, citing deficiencies related to the chemistry and manufacturing of the product. "We see Evolus' entry into this market as very disruptive," Evolus Chief Executive Officer David Moatazedi said in an interview prior to the FDA's decision.
The approval of Evolus's Jeuveau to treat frown lines comes about eight months after the agency declined to approve the drug, citing deficiencies related to the chemistry and manufacturing of the product. "We see Evolus' entry into this market as very disruptive," Evolus Chief Executive Officer David Moatazedi said in an interview prior to the FDA's decision. Evolus expects Jeuveau to be priced between 20 and 25 percent lower than Botox and is likely to be available throughout the United States at physician offices starting Spring 2019, the company said.
The first new aesthetic neurotoxin to rival Allergan Plc’s Botox in almost a decade may be approved in time for Valentine’s Day. Evolus Inc. Chief Executive Officer David Moatazedi says his company remains on track for a spring 2019 launch for its experimental wrinkle treatment, DWP-450. The Food and Drug Administration is now expected to make a decision on the drug by February 2 after the company failed to secure approval in May when the agency had questions on the company’s chemistry, manufacturing and controls processes.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 18) Abbott Laboratories (NYSE: ABT )(reported better-than-expected ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...
Jim Cramer hears from Evolus President and CEO David Moatazedi about his company's cheaper rival to Allergan's Botox.